StreetAlpha.app
Home › Stocks › SLN

Silence Therapeutics plc (SLN)

Healthcare
$19.80
▲ +0.00%
LAST CLOSE · NOV 17

Silence Therapeutics develops siRNA medicines that switch off disease-linked genes, with candidates for blood, heart and obesity conditions. It last closed at $19.80 on Nov 17, up 0.00% on the day. In the past 30 days there were 14 dark pool prints totaling $43.6M, the largest $12.1M.

AI Auto Pilots
Is SLN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$456K
−98.2% vs a year ago
Net income
−$51.4M
−11276.5% margin
EPS (diluted)
−$0.35
Free cash flow
−$44.1M
−9681.6% margin
Valuation
Market cap
$3.7B
186.6M shares
P/E
–
No P/E while losing money
Price to sales
8102.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$247.7M
At Sep 30
Shareholder equity
$215.0M
Shares outstanding
186.6M
At Sep 30
ExchangeNasdaq
Financials history
FY2022: $21.7M$21.7MFY2022FY2023: $31.6M$31.6MFY2023FY2024: $43.3M$43.3MFY2024FY2025: $559K$559KFY2025

From SLN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Hold
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Hold
1firm
0 Buy1 Hold0 Sell
Only 1 firm rated SLN in the past 90 days, not enough for a consensus
Average 12-month target
$20.00
▲ 1.0% upside

Based on 1 analyst who set a price target on SLN in the past 90 days. The average target is $20.00, with a high of $20.00 and a low of $20.00, compared with the last close of $19.80.

Low $20.00Avg $20.00High $20.00
Blue marker: last close $19.80
Highest target$20.00
Average target$20.00
Lowest target$20.00
Latest rating changes
HC Wainwright & Co.Downgrade
Oct 21Hold$75 → $20
Morgan StanleyMaintained
Aug 11Buy$32
HC Wainwright & Co.Reiterated
Jun 17Buy$75
DateFirmActionRatingPrice target
Oct 21HC Wainwright & Co.DowngradeHold$75 → $20
Aug 11Morgan StanleyMaintainedBuy$32
Jun 17HC Wainwright & Co.ReiteratedBuy$75
Loading…

Technical Analysis

SLN · as of the Nov 17 close · updated after every close
Uptrend, overbought

The stock is 0% above its 20 day and 25% above its 50 day average. It is 50% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 78), overbought. The nearest support is the Pivot S1 at $19.78, and the nearest resistance the swing high (Nov 3) at $19.82.

Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityLow, 1.8%/day
Key levels
$19.8652 week high+0.3%
$19.82Pivot R1+0.1%
$19.82Swing high (Nov 3)+0.1%
$19.80Pivot+0.0%
$19.80Last close
$19.78Pivot S1−0.1%
$19.7620 day average−0.2%
$19.70Swing low (Nov 9)−0.5%
$14.8950 day average−24.8%
$13.51100 day average−31.8%
$9.93200 day average−49.8%
$4.1952 week low−78.8%
Indicators
RSI (14)77.68Overbought above 70Overbought
MACD1.44Below its signal lineBearish
Stochastic71.0Middle of its rangeNeutral
ADX (14)57.2Strong uptrend
Williams %R-35.5Oversold below −80, overbought above −20Neutral
CCI (20)86.1Oversold below −100, overbought above 100Neutral
Rate of change+0.1%Change over 10 sessionsBullish
ATR (14)$0.35Typical daily range, 1.8% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for SLN

What happened before

See how SLN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SLN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SLN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SLN in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
14
Notional
$43.6M
Largest print
$12.1M
Loading…

SLN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲72 buying vs 28 selling
  • ▲Held by funds +13.2 pts
  • ▲Funds holding +20
  • ▲Superinvestors: 5 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9272+27.8%
In funds' top 1041+300.0%
Held by funds25.9%12.6%+13.2 pts
New / increased34 / 3820 / 22+71.4%
Reduced / sold out15 / 1318 / 4+27.3%
Put/call ratio0.070.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SLN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SLN is in one of them and how their past SLN trades turned out.

SLN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SLN in an article yet. Here's the latest on the wider market.

About Silence Therapeutics

Silence Therapeutics is a biotechnology company based in London that develops small interfering RNA, or siRNA, medicines. These molecules work by switching off specific genes linked to disease in the liver, which lowers the proteins those genes produce. Its candidates target rare blood disorders, heart and cholesterol conditions, and obesity. The company is also seeking outside partners to help take some of these treatments further.

Headquarters
London